Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 20Docetaxel 8Carboplatin 8Fluorouracil 6Cisplatin 6Nivolumab 5fludarabine 4Trastuzumab 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Cyclophosphamide 4Biopsy 4Bevacizumab 4fludarabine phosphate 3durvalumab 3atezolizumab 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Capecitabine 3Albumin-Bound Paclitaxel 3ulixertinib 2tisotumab vedotin 2spartalizumab 2belinostat 2adavosertib 2X-Rays 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Medicare Part B × Head & Neck × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡